ID
13744
Beschrijving
A Study of AS1411 Combined With Cytarabine in the Treatment of Patients With Primary Refractory or Relapsed Acute Myeloid Leukemia; ODM derived from: https://clinicaltrials.gov/show/NCT01034410
Link
https://clinicaltrials.gov/show/NCT01034410
Trefwoorden
Versies (1)
- 02-03-16 02-03-16 -
Houder van rechten
CC BY-NC 3.0
Geüploaded op
2 maart 2016
DOI
Voor een aanvraag inloggen.
Licentie
Creative Commons BY-NC 3.0
Model Commentaren :
Hier kunt u commentaar leveren op het model. U kunt de tekstballonnen bij de itemgroepen en items gebruiken om er specifiek commentaar op te geven.
Itemgroep Commentaren voor :
Item Commentaren voor :
U moet ingelogd zijn om formulieren te downloaden. AUB inloggen of schrijf u gratis in.
Eligibility Acute Myeloid Leukemia NCT01034410
Eligibility Acute Myeloid Leukemia NCT01034410
- StudyEvent: Eligibility
Beschrijving
Exclusion Criteria
Alias
- UMLS CUI
- C0680251
Beschrijving
an initial diagnosis of acute promyelocytic leukemia (as defined by french-american-british criteria (bennett 1976))
Datatype
boolean
Alias
- UMLS CUI [1]
- C0023487
Beschrijving
secondary aml, defined as aml evolving from antecedent hematological disorder or prior exposure to leukemogenic therapy or agent
Datatype
boolean
Alias
- UMLS CUI [1]
- C0280449
Beschrijving
clinically active cns leukemia
Datatype
boolean
Alias
- UMLS CUI [1]
- C1332884
Beschrijving
previously received a total cumulative dose of cytarabine > 6g/m2 in the last 6 months
Datatype
boolean
Alias
- UMLS CUI [1,1]
- C0010711
- UMLS CUI [1,2]
- C2986497
Beschrijving
previously received > 1 induction regimen (defined as 1 or 2 cycles of a drug or a drug combination administered as remission induction therapy)
Datatype
boolean
Alias
- UMLS CUI [1]
- C3179010
Similar models
Eligibility Acute Myeloid Leukemia NCT01034410
- StudyEvent: Eligibility
C0205269 (UMLS CUI [1,2])
C0205269 (UMLS CUI [1,2])
C1982687 (UMLS CUI [2])
C0023467 (UMLS CUI [2,1])
C0277556 (UMLS CUI [2,2])
C2986497 (UMLS CUI [1,2])